ProCE Banner Activity

An Expert’s Guide to ASH 2021: A Preview of the Top Abstracts

Conference Coverage
Clinical Thought
Review experts’ perspectives on the most clinically relevant data on malignant and nonmalignant hematology to be presented at the ASH 2021 annual meeting, including key insights and the latest data you need to understand and integrate into your practice.

Released: December 08, 2021

Expiration: December 07, 2022

Share

Faculty

John M. Burke

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Amy E. DeZern

Amy E. DeZern, MD, MHS

Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Peter Martin

Peter Martin, MD

Professor of Medicine
Weill Cornell Medicine
New York, New York

Mark A. Schroeder

Mark A. Schroeder, MD

Associate Professor of Medicine
Division of Oncology
Department of Medicine
Washington University School of Medicine in St Louis
St Louis, Missouri

Sujit Sheth

Sujit Sheth, MD

Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Srdan Verstovsek

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

John M. Burke, MD, has disclosed that he has received consulting fees from AbbVie, Adaptive Biotechnologies, AstraZeneca, Epizyme, Kura, MorphoSys, Roche/Genentech, and Verastem and fees for non-CME/CE services from Seattle Genetics.

Amy E. DeZern, MD, MHS

Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Amy E. DeZern, MD, MHS, has disclosed that she has received consulting fees from Bristol-Myers Squibb, Geron, Gilead Sciences, Novartis, Taiho, and Takeda.

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji K. Kumar, MD, has disclosed that he has received funds for research support from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, MedImmune, Oncopeptides, Takeda, and TeneoBio and consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Oncopeptides, and Takeda

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb, Celgene, Janssen, and Takeda; consulting fees from AbbVie, Bluebird, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, and Takeda; and fees for non-CME/CE services from TG Therapeutics.

Peter Martin, MD

Professor of Medicine
Weill Cornell Medicine
New York, New York

Peter Martin, MD, has disclosed that he has received consulting fees from BeiGene, BMS/Celgene, Gilead/Kite, Incyte, Janssen, Karyopharm, Merck, MorphoSys, Regeneron, Takeda.

Mark A. Schroeder, MD

Associate Professor of Medicine
Division of Oncology
Department of Medicine
Washington University School of Medicine in St Louis
St Louis, Missouri

Mark A. Schroeder, MD, has disclosed that he has received consulting fees from AbbVie, Merck, and Takeda; funds for research support from Amgen, Celgene, Cellect, Fortis, Genentech, Incyte, Janssen, PBD Inc., Sanofi Genzyme, and Seattle Genetics and fees for non-CME/CE services from Astellas, Dova, Flatiron, GlaxoSmithKline, Incyte, Janssen, Novo Nordisk, Partners Therapeutics, Pfizer, and Sanofi Genzyme.

Sujit Sheth, MD

Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Sujit Sheth, MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb/Celgene, DisperSol, and La Jolla and consulting fees from Agios, Bristol-Myers Squibb/Celgene, and CRISPR/Vertex.

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Srdan Verstovsek, MD, PhD, has disclosed that he has received funds for research support from AstraZeneca, Blueprint, Celgene, CIT BioPharma, Genentech, Gilead Sciences, Incyte, Italfarmaco, Novartis, NS Pharma, Pharma Essentia, Promedior, Protagonist Therapeutics, Roche, and Sierra Oncology and consulting fees from Bristol-Myers Squibb, Celgene, Constellation, Incyte, Novartis, and Sierra Oncology.

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD, has disclosed that she has received consulting fees from AbbVie/Genentech, Astellas/Jazz, Bristol-Myers Squibb/Celgene/Kite, Gilead Sciences, GlaxoSmithKline, Kura Oncology, Mana, Novartis, Pfizer, Rafael, Stemline, and Takeda and fees for non-CME/CE services from Dava Oncology, Kura Oncology, Pfizer, and Stemline.